Journal article
Prospective Evaluation of the Impact of the 21‐Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node‐Positive Breast Cancer in Ontario, Canada
Abstract
BACKGROUND: The 21-gene Recurrence Score (RS) assay is only reimbursed in Ontario for node-negative and micrometastatic node-positive (N+) early-stage breast cancer (EBC). We carried out a prospective study to evaluate the impact of the assay on treatment decisions for women with N+ EBC.
SUBJECTS, MATERIALS, AND METHODS: Women with estrogen receptor-positive, human epidermal growth receptor 2-negative EBC and one to three positive axillary …
Authors
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew‐Shue M; Chao C; Eisen A
Journal
The Oncologist, Vol. 23, No. 7, pp. 768–775
Publisher
Oxford University Press (OUP)
Publication Date
July 1, 2018
DOI
10.1634/theoncologist.2017-0346
ISSN
1083-7159